Navidea Biopharmaceuticals (NAVB) Shares are Up 26.16%

Navidea Biopharmaceuticals (NAVB) : Traders are bullish on Navidea Biopharmaceuticals (NAVB) as it has outperformed the S&P 500 by a wide margin of 109.09% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 25.49%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 26.16% in the last 1 week, and is up 104.85% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 63.88% and the 50-Day Moving Average is 81.15%.The 200 Day SMA reached 12.81% Navidea Biopharmaceuticals, Inc is up 68.85% in the last 3-month period. Year-to-Date the stock performance stands at -22.56%.


Average consensus for the company shares for this week is a Strong Sell . Navidea Biopharmaceuticals (NYSEMKT:NAVB): The stock opened at $1.02 and touched an intraday high of $1.05 on Friday. During the day, the stock corrected to an intraday low of $0.9012, however, the bulls stepped in and pushed the price higher to close in the green at $1.03 with a gain of 17.98% for the day. The total traded volume for the day was 5,180,100. The stock had closed at $1.03 in the previous trading session.

Navidea Biopharmaceuticals, Inc. is a precision medicine company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents. The Company is developing multiple precision-targeted products based on the Manocept platform. The Manocept platform serves as the molecular backbone of Lymphoseek (technetium Tc 99m tilmanocept) injection, the first product developed by the Company based on the platform. Lymphoseek is a receptor-targeted, small-molecule radiopharmaceutical used in the evaluation of lymphatic basins that may have cancer involvement in patients. NAV4694 is a fluorine-18 radiolabeled PET imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimers disease (AD) and mild cognitive impairment. NAV5001 is an iodine-123 radiolabeled SPECT imaging agent being developed as an aid in the diagnosis of Parkinsons disease (PD) and other movement disorders.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.